Table 2: TOP3A Genetic Variant Association with Doxorubicin Sensitivity in LCLs

Tana Takacova published a dataset on figshare in May 2026 containing results from a pharmacogenomic study of doxorubicin. The data likely includes EC50 cytotoxicity values for 184 human lymphoblastoid cell lines of European ancestry, genotyped for 1,126 polymorphic sites across five topoisomerase genes. It identifies a specific genetic variant, rs113270903 in TOP3A, as a biomarker for drug sensitivity.

Use Cases

• Validate the association between rs113270903 and doxorubicin EC50 values based on the reported analysis.
• Investigate genetic determinants of chemotherapy sensitivity based on the 1,126 polymorphic sites across topoisomerase genes.
• Compare doxorubicin cytotoxicity profiles between training (n=120) and test (n=64) cell line cohorts.
• Perform secondary analysis on the EC50 values for 184 lymphoblastoid cell lines mentioned in the description.

Strengths

• Includes data from a defined cohort of 184 human lymphoblastoid cell lines.
• Reports a replicated genetic association (rs113270903) with a specific effect size (approx. 30% lower EC50).
• Analysis covers 1,126 polymorphic sites across five candidate genes.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data is limited to cell lines of European ancestry, which may not generalize to other populations.

Provenance

Source

Tana Takacova via figshare.

Collection Method

EC50 values determined via fluorescence-activated cell sorting; genotype data retrieved from the 1,000 Human Genome and HapMap Projects.

Freshness

Last updated 2026-05-13 07:30:27; freshness should be verified.

Geography

Cell lines are of European ancestry.